Buprenorphine Cost Effectiveness

More documents

Recommendations

Info

Conclusions • Office-based buprenorphine for clinically stable patients is cost-effective compared to no treatment using accepted thresholds for medical treatment in the US • Price reductions have a small effect on costeffectiveness findings – Not appropriate to refuse treatment coverage until generic buprenorphine/naloxone is available on the basis of cost-effectiveness • Lack of certainty about quality-of-life weights reduces robustness of findings – Further research about quality of life on and off buprenorphine is necessary 18
• David Fiellin, MD • Jared Leff, MS Acknowledgments • Daniel Polsky, PhD • Brent Moore, PhD • Emlyn Jones, MD • Ashley Eggman, MS 19
Page 1 and 2: Buprenorphine Cost Effectiveness Br
Page 3 and 4: Buprenorphine Cost • Cost has bee
Page 5 and 6: Cost-effectiveness ≠ Cost saving
Page 7 and 8: Questions Policy Makers Should Ask
Page 9 and 10: Cost-effectiveness vs cost-benefit?
Page 11 and 12: Published Cost-Effectiveness Studie
Page 13 and 14: Enter In Treatment Off Drugs In Tre
Page 15 and 16: Cohort Retention In Treatment By Mo
Page 17: Limitations • Cohort treated at a

Buprenorphine Cost Effectiveness

Create successful ePaper yourself

Delete template?

Save as template?